New Anti-Virus Can Heal Hepatitis C

Scientists have successfully cured hepatitis C patients with two new types of antiviral products

Hepatitis C is transmitted through the virus in the body fluid and eventually damages the liver. Unlike other forms of hepatitis, it does not have a vaccine. The only treatment is through the combination of interferon and protease inhibitors. However, the treatment has many side effects and has a complex management. At the same time, the product does not have any effect on what is commonly known as genotype 1 hepatitis C. If the patient is not treated effectively, he may eventually get cancer.

In the medical journal “Liu Ye” magazine, a trial consisting of sofosbuvir and ledipasvir was conducted on Tuesday. In the trial, 100 patients and genotype 1 hepatitis C patients were divided into one group and one of them was taken for 8 to 12 weeks. Of the previously failed participants, 40 had a negative effect on the product and half had cirrhosis.

Twelve weeks later, 97% of participants performed experiments that scientists called "sustained virological responses." This meant that they did not detect the hepatitis C virus. Although the patient suffered from various side effects, including nausea, anemia, respiratory infections and headaches, experts believe that these conditions are not serious.

Professor Eric Lawitz from the University of Texas led the study and said: "The results of this trial show that the fixed-dose combination sofosbuvir and ledipasvir can obtain cirrhosis or in vivo resistant strains for those who do not have access to existing therapies. Patients with the virus are treated effectively by oral means.

Charles Gore, Chief Executive Officer of Hepatitis C Trust, said: “The new product mix is ​​good news. Even people who are difficult to treat using existing methods can actually be cured through this product. This is really an order. Incredible achievements.

Although new treatments have emerged, only 3% of hepatitis C patients are being treated in the United Kingdom. Therefore, we must allow more patients to accept this new type of treatment through different ways to help patients recover.

Professor Margaret Hellard of the Burnet Research Institute in Melbourne, Australia, commented: “As a proof-of-concept study, the demo has a very high response rate to prove the existence of cirrhosis, the failure of previous treatments or the presence of resistance However, it is worth noting that the scale of the study is very small, and that there is only a short follow-up at a single site, so it is worth considering whether representative samples and early clinical trial results can be generalized to the real world. The experiment is still one-sided, but the effect of this result is still worthy of attention. ”

Stearate

Pvc Stearate,Chemical Stearate,Pvc Zinc Stearate,Powder Calcium Stearate

Hebei Fengse New Material Technology Co.ltd. , https://www.hbfengsechemical.com